MarketCap
Facebook
X
Telegram
Liminal BioSciences Revenue | LMNL
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Liminal BioSciences
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 401 K | 643 K | 724 K | 745 K | 24.6 M | 22.3 M | 16.4 M | 24.5 M | 23 M | 20.6 M | 23.3 M | 17.6 M |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 24.6 M | 401 K | 14.6 M |
Quarterly Revenue Liminal BioSciences
| 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 401 K | - | - | - | 643 K | - | - | - | 724 K | - | 540 K | - | 745 K | - | 762 K | - | 24.6 M | - | - | - | 22.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in CAD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 24.6 M | 401 K | 6.35 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Kadmon Holdings, Inc.
KDMN
|
8.29 M | - | - | $ 1.7 B |  USA |
 |
Neos Therapeutics, Inc.
NEOS
|
64.6 M | - | -2.54 % | $ 57.2 M | USA |
 |
Osmotica Pharmaceuticals plc
OSMT
|
178 M | - | -10.74 % | $ 89.9 M | USA |
 |
Pandion Therapeutics, Inc.
PAND
|
8.78 M | - | - | $ 1.77 B | USA |
 |
Translate Bio, Inc.
TBIO
|
139 M | - | - | $ 2.81 B | USA |
 |
Trillium Therapeutics Inc.
TRIL
|
148 K | - | - | $ 1.94 B |  Canada |
 |
Acceleron Pharma Inc.
XLRN
|
74 M | - | - | $ 10.9 B | USA |
 |
Zealand Pharma A/S
ZEAL
|
293 M | - | 0.52 % | $ 821 M |  Danmark |
 |
Zogenix, Inc.
ZGNX
|
13.6 M | - | -4.97 % | $ 664 M | USA |
 |
ZIOPHARM Oncology, Inc.
ZIOP
|
146 K | - | -7.58 % | $ 264 M | USA |
 |
Leap Therapeutics
LPTX
|
1.5 M | - | 368.57 % | $ 41.9 M | USA |
 |
Aptorum Group Limited
APM
|
431 K | - | - | $ 5.72 M |  China |
 |
FSD Pharma
HUGE
|
257 K | - | 5743.5 % | $ 69.7 M | Canada |
 |
BioAtla
BCAB
|
300 K | $ 1.74 | 0.64 % | $ 102 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
589 M | - | - | $ 3.85 B | USA |
 |
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M | Canada |
 |
ADiTx Therapeutics
ADTX
|
3.2 K | - | - | $ 374 | USA |
 |
Aeterna Zentaris
AEZS
|
7.5 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
130 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
123 M | - | 1.93 % | $ 17.4 M | USA |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
1 B | - | - | $ 5.18 B | USA |
 |
Avenue Therapeutics
ATXI
|
1.4 M | - | -52.27 % | $ 4.45 M | USA |
 |
AstraZeneca PLC
AZN
|
58.7 B | - | - | $ 96.9 B |  Britain |
 |
BeiGene, Ltd.
BGNE
|
5.34 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bio-Path Holdings
BPTH
|
37 K | - | - | $ 100 K | USA |
 |
Cara Therapeutics
CARA
|
7.14 M | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
129 M | - | -0.88 % | $ 598 M | USA |
 |
Caladrius Biosciences
CLBS
|
170 K | - | -16.75 % | $ 25.8 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
43 K | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
43 K | - | -4.36 % | $ 27 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
4.01 M | - | 11.68 % | $ 8.97 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
6.36 M | - | -5.68 % | $ 8.28 M | USA |
 |
Enochian Biosciences
ENOB
|
42.8 K | - | - | $ 40.5 M | USA |
 |
Esperion Therapeutics
ESPR
|
403 M | - | - | $ 661 M | USA |
 |
Evofem Biosciences
EVFM
|
20.2 M | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
813 K | - | 49.81 % | $ 13.2 M | USA |
 |
FibroGen
FGEN
|
6.44 M | - | - | $ 889 M | USA |